European Pharmaceutical Review
OCTOBER 7, 2022
billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes. This is especially beneficial as a way of decreasing potential side effects.
World of DTC Marketing
MAY 16, 2022
Mounjaro, Lilly’s new diabetes drug, is sure to be in high demand initially after launch, but patients should be aware of its side effects. According to Lilly side, the effects include “Mounjaro may cause tumors in the thyroid, including thyroid cancer and Inflammation of the pancreas (pancreatitis).”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JANUARY 7, 2021
MINUTE READ: Big pharma should take a good, hard look at small biotech companies and try to better understand how they succeed and are able to make strategic decisions faster without multi-levels of bureaucracy. By 2030, low retention will, on average, cost the US $430 billion annually.
Medico Reach
FEBRUARY 8, 2023
With the use of trailblazing digital platforms, cost-effective technologies, big data analytics, blockchain, and artificial intelligence (AI), the landscape is undergoing a massive transition. The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. million by 2030.
pharmaphorum
DECEMBER 21, 2022
Likewise, between 2030 and 2050, the World Health Organization estimates that climate change will be responsible for around 250,000 additional deaths per year. Innovation – using technology to solve problems without creating harmful side-effects. This will provide an impetus for others in the sector to follow suit.
PM360
AUGUST 9, 2022
billion in 2030 at a CAGR of 9.2%. Pharma Manufacturer Solutions. 1 GoodRx’s partnerships with pharma manufacturers and other key stakeholders in the healthcare industry enable them to offer discounts which have helped patients fill at least 80 million prescriptions that they otherwise could not afford. from 2021 and reach $4.2
pharmaphorum
SEPTEMBER 30, 2022
GlobalData notes that the side effect could be a barrier for lecanemab use as it will require patient monitoring, but points out that the rates are a “significant improvement” on Aduhelm, which had an ARIA-E rate of 35% of patients taking the approved dose in clinical trials. .”
Expert insights. Personalized for you.
83 
Let's personalize your content